tiprankstipranks
Trending News
More News >

Shandong Xinhua Pharmaceutical Secures Approval for Pregabalin Oral Solution

Story Highlights
Shandong Xinhua Pharmaceutical Secures Approval for Pregabalin Oral Solution

Confident Investing Starts Here:

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an announcement.

Shandong Xinhua Pharmaceutical Company Limited has announced that it has received a Drug Registration Certificate for its Pregabalin oral solution from the National Medical Products Administration. This approval marks a significant step for the company, allowing it to produce and market the drug, which is used in the treatment of postherpetic neuralgia, fibromyalgia, and partial seizures, thereby potentially enhancing its market position and expanding its product offerings.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, specializing in the production of a range of pharmaceutical products. The company focuses on the development and manufacturing of prescription drugs, with a market emphasis on domestic production.

YTD Price Performance: -6.37%

Average Trading Volume: 2,139,988

Technical Sentiment Signal: Hold

Current Market Cap: HK$8.49B

See more insights into 0719 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App